Li-Pri (Lidocaine, Prilocaine)

• Li-Pri is used for topical local anesthesia of the skin and for procedural analgesia in minor skin interventions.
• Minor skin excisions: provides rapid onset anesthesia to reduce procedural pain.
• Dermatologic surgery: numbs the treatment area, improving patient comfort during lesion removal.
• Superficial wound debridement: offers analgesia that facilitates cleaning of minor wounds.
• Laser therapy: delivers effective skin numbness to minimize discomfort during laser procedures.

• Lidocaine and prilocaine act by reversibly blocking voltage‑gated sodium channels on neuronal membranes, preventing the initiation and propagation of action potentials. This inhibition of nerve impulse conduction results in loss of sensation in the applied area, producing a localized anesthetic effect without affecting systemic neural activity when used as directed.

Topical application of Li-Pri may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Transient erythema: mild redness at the application site.
• Localized itching: brief pruritus that resolves spontaneously.
• Mild swelling: slight edema without systemic involvement.
• Temporary tingling: sensation of pins and needles that fades.

Serious or Rare Side Effects

• Methemoglobinemia: rare elevation of methemoglobin levels requiring medical attention.
• Allergic contact dermatitis: severe skin reaction with blistering or ulceration.
• Systemic toxicity: signs such as dizziness, seizures, or cardiac arrhythmia in case of excessive absorption.

• When using Li-Pri, several safety considerations should be observed to minimize risk.
• Patient assessment: evaluate skin integrity and allergy history before application.
• Area size limitation: restrict total applied surface to recommended maximum to avoid systemic exposure.
• Avoid mucous membranes: do not apply on eyes, ears, or genitals.
• Concurrent anesthetics: limit use with other topical anesthetics to prevent additive toxicity.
• Medical conditions: use cautiously in patients with cardiovascular disease or anemia.
• Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture and direct sunlight.

Li-Pri can interact with other medicines, influencing its safety or effectiveness.

Major Interactions (Avoid)

• Class I antiarrhythmic agents (e.g., quinidine, procainamide): may potentiate cardiac toxicity.
• CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): can increase plasma levels of lidocaine.
• Other local anesthetics: concurrent use raises risk of systemic toxicity.

Moderate Interactions (Monitor Closely)

• Beta‑blockers (e.g., propranolol): may enhance bradycardic effects.
• Diuretics (e.g., furosemide): can reduce plasma protein binding, raising free drug concentration.
• Alcohol: may augment central nervous system depression.